Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Giancarlo Pizza is active.

Publication


Featured researches published by Giancarlo Pizza.


Progress in drug research | 1994

Transfer factor 1993: New frontiers

H. Hugh Fudenberg; Giancarlo Pizza

Adoptive transfer of antigen-specific cell-mediated immunity in humans, first demonstrated by Lawrence [1] in 1949, opened a new avenue of research that has led both to increased understanding of basic immune mechanisms and to the development of many forms of immunomodulant therapy, alone or in combination with other immu-notherapeutic or chemotherapeutic agents. Lawrence originally showed that transfer of intact viable lymphocytes from a normal tuberculin skin test-positive donor for a given antigen to a normal recipient, skin test-negative for that antigen, resulted in a conversion (“transfer”) of the recipient to skin-test positivity; however, this observation created little interest in the immunologic community for several reasons. In 1955, the lymphocyte was mentioned for the first time as an immunologic organ. (Before this, the lymphocyte had been studied in hematologic rather than in immunologic terms.)


Biotherapy | 1996

Preliminary observations using HIV-specific transfer factor in AIDS.

Giancarlo Pizza; Francesco Chiodo; Vincenzo Colangeli; Francesco Gritti; Enzo Raise; H. Hugh Fudenberg; Caterina De Vinci; Dimitri Viza

Twenty five HIV-1-infected patients, at various stages (CDC II, III and IV) were treated orally with HIV-1-specific transfer factor (TF) for periods varying from 60 to 1870 days. All patients were receiving antiviral treatments in association with TF. The number of lymphocytes, CD4 and CD8 subsets were followed and showed no statistically significant variations. In 11/25 patients the number of lymphocytes increased, whilst in 11/25 decreased; similarly an increase of the CD4 lymphocytes was observed in 11/25 patients and of the CD8 lymphocytes in 15/25. Clinical improvement or a stabilized clinical condition was noticed in 20/25 patients, whilst a deterioration was seen in 5/25. In 12/14 anergic patients, daily TF administration restored delayed type hypersensitivity to recall antigens within 60 days. These preliminary observations suggest that oral HIV-specific TF administration, in association with antiviral drugs, is well tolerated and seems beneficial to AIDS patients, thus warranting further investigation.


Biotherapy | 1996

A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer.

Giancarlo Pizza; Caterina De Vinci; Diego Cuzzocrea; Domenico Menniti; Ernesto Aiello; Paolo Maver; Giuseppe Corrado; Piero Romagnoli; Ennio Dragoni; Giuseppe LoConte; Umberto Riolo; Aldopaolo Palareti; Paolo Zucchelli; Vittorio Fornarola; Dimitri Viza

As conventional treatments are unsuccessful, the survival rate of stage D3 prostate cancer patients is poor. Reports have suggested the existence of humoral and cell-mediated immunity (CMI) against prostate cancer tumour-associated antigens (TAA). These observations prompted us to treat stage D3 prostate cancer patients with an in vitro produced transfer factor (TF) able to transfer, in vitro and in vivo, CMI against bladder and prostate TAA. Fifty patients entered this study and received one intramuscular injection of 2–5 units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed that complete remission was achieved in 2 patients, partial remission in 6, and no progression of metastatic disease in 14. The median survival was 126 weeks, higher than the survival rates reported in the literature for patients of the same stage.


International Journal of Cancer | 2001

Immunotherapy of metastatic kidney cancer.

Giancarlo Pizza; Caterina De Vinci; Giuseppe L. O. Conte; Paolo Maver; Ennio Dragoni; Ernesto Aiello; Vittorio Fornarola; Tiziano Bergami; Luciano Busutti; Stefano Boriani; Aldopaolo Palareti; Rodolfo Capanna

From April 1986 to September 2000, 122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL‐2 U and 26 × 106 LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3‐day cycle of monthly IL‐2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy (n = 89) represent our historical controls. Adverse clinical side effects related to treatment were negligible. CR (n = 11) and PR (n = 13) were noticed in 24/122 patients. Of 24 responding patients, 17 resumed progression, whereas 7 remain in remission 11–69 months later. The overall median survival of treated patients (28 months) was 3.5‐fold higher than the median survival of historical controls (7.5 months), and a Kaplan‐Meier curve showed 25% survival 11 years after the beginning of immunotherapy. Apparently, the addition of IL‐2 by inhalation improved survival. The present immunotherapy protocol appears to be efficacious, safe, devoid of adverse side effects, far less costly than others and able to offer a good quality of life to MRCC patients; if confirmed in a multicenter trial, it could set the basis for developing low‐dose immunomodulatory treatments.


Experimental Biology and Medicine | 1985

Transfer factor for the treatment of HBsAg-positive chronic active hepatitis.

E. Roda; D. Viza; Giancarlo Pizza; L. Mastroroberto; J. Phillips; C. De Vinci; L. Barbara

Abstract Transfer factor was obtained from four patients having recovered from acute type-B viral hepatitis. It was replicated in vitrousing the LDV/7 lymphoblastoid cell line. This in vitro-produced transfer factor specific for hepatitis B (TFdL-H) was administered to 10 randomly selected patients with biochemically and histologically proven HBsAg-positive chronic active hepatitis (CAH) at 15-day intervals over a 6-month period. In three out of four initially HBeAg-positive patients, anti-HBe antibodies appeared when the HBeAg disappeared. In one of these patients and in two other HBsAg-positive patients, the appearance of anti-HBs antibodies was noted. The improvement in several biochemical parameters of the TFdL-H patients was statistically significant when compared with those of another group of 10 randomly selected untreated CAH patients. Liver biopsies in six out of eight treated patients showed a histological improvement at the end of the treatment. These results suggest that TFdL-H may be used with beneficial effect for the treatment of HBsAg-positive CAH.


Biotherapy | 1996

Transfer Factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy

Vladimiro Pilotti; Mario Mastrorilli; Giancarlo Pizza; Caterina De Vinci; Luciano Busutti; Aldopaolo Palareti; Gozzetti G; Antonino Cavallari

The rationale for using transfer factor (TF) in lung cancer patients is that the possibility of improving their cell-mediated immunity to tumour associated antigens (TAA) may improve their survival. From Jan 1984 to Jan 1995, 99 non-small cell lung cancer (NSCLC) resected patients were monthly treated with TF, extracted from the lymphocytes of blood bank donors. In the same period, 257 NSCLC resected patients were considered as non-treated controls. The survival rates of the TF treated group appear significantly improved both for patients in stages 3a and 3b, and patients with histological subtype “large cell carcinoma” (P<0.02). Survival of TF treated patients is also significantly higher (P<0.02) for patients with lymphnode involvement (N2 disease). The results of this study suggest that the administration of TF to NSCLC resected patients may improve survival.


Cancer Treatment Reviews | 1989

Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma

Elizabeth A. Fagan; Melanie S. Pulley; Astrid Limb; R. Wolstencroft; Charmaine Cranenburgh; Caterina De Vinci; John Karani; Michael J Michell; Heather Nunnerley; Shams Zaman; Giancarlo Pizza; D.C. Dumonde; Roger Williams

We assessed the feasibility of using lymphokine-activated killer cells (adoptive immunotherapy) with infusions of interleukin-2 when given regionally in three patients with unresectable primary hepatocellular carcinoma (PHC). In 2 patients, 2 cycles, which included a bolus of LAK (10(7) to 10(8) cells followed by a 4-hourly infusion of IL-2 were administered via selective arterial catheterization of the hepatic artery. One further patient received 3 cycles of IL-2 alone by direct intralesional and perilesional injections. Minimal toxicity was observed and side effects such as fever were comparable to those observed with systemic infusions of IL-2 alone. Serial alpha-fetoprotein (AFP) levels initially fell but subsequently rose within 2 to 4 weeks of therapy. AFP levels had not reached pre-treatment values at 4 months in 2 patients, 1 of whom was alive and well at 15 months follow-up.


Biotherapy | 1996

Orally administered HSV-specific transfer factor (TF) prevents genital or labial herpes relapses.

Giancarlo Pizza; Dimitri Viza; Caterina De Vinci; Aldopaolo Palareti; Diego Cuzzocrea; Vittorio Fornarola; Roberto Baricordi

Forty-four patients suffering from genital (22) and labial (22) herpes were orally treated with HSV-1/2-specific transfer factor(TF). TF was obtained by in vitro replication of a HSV-1/2-specific bovine dialysable lymphocyte extract. Treatment was administered bi-weekly the first 2 weeks, and then weekly for 6 months, most patients received 2–3 courses. The total observation period for all patients before treatment was 26660 days, with 544 relapses, and a relapse index of 61.2, whereas the cumulative observation period during and after treatment was 16945 days, with a total of 121 relapsing episodes and a cumulative RI of 21.4 (P<0.0001). Results were equally significant when the 2 groups of patients (labial and genital) were considered separately. These observations confirm previous results obtained with bovine HSV-specific TF, and warrant further studies to establish HSV-specific TF as a choice of treatment for preventing herpes recurrences.


Biotherapy | 1996

Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: A pilot study

U. Prasad; Mohd Amin Jalaludin; Pathmanathan Rajadurai; Giancarlo Pizza; Caterina De Vinci; Dimitri Viza; Paul H. Levine

Overall survival of nasopharyngeal carcinoma (NPC) at UICC stage IV still remains unsatisfactory even with combination chemotherapy (CT) and radio-therapy (RT). In view of the association of reactivation of Epstein-Barr virus (EBV) with the development and recurrence of NPC, immunotherapy in the form of transfer factor (TF) with specific activity against EBV (TF-B1) was suggested as an adjuvant to a combination of CT and RT in order to improve survival. In the present study, 6 UICC Stage IV patients received TF-B1 and another 6 patients matched for disease stage were given TF prepared from peripheral blood leucocytes (TF-PBL). Results were compared with another 18 patients matched by age, sex, and stage of disease who received standard therapy without TF during the same period (C group). After a median follow up of 47.5 months, the survival for the TF-B1 group was found to be significantly better (P=<0.05) than the PBL and C group. While the 8 patients with distant metastasis (DM), not treated with TF-B1 (6 in the control and 2 in the PBL group), died due to progressive disease (average survival being 14.3 months), both patients with DM in the TF-B1 group had complete remission: one died of tuberculosis after surviving for 3.5 years and another is still alive, disease free, after 4.2 years. Although the series involved a small number of cases, the apparent effect of adjuvant immunotherapy in the form of TF with anti-EBV activity is of considerable interest.


Biotherapy | 1996

Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and Zidovudine (ZDV)

Enzo Raise; Luca Guerra; Dimitri Viza; Giancarlo Pizza; Caterina De Vinci; Maria Luisa Schiattone; Leonarda Rocaccio; Maria Cicognani; Francesco Gritti

The efficiency of HIV-1 specific transfer factor (TF) administration, combined with Zidovudine (ZDV), in asymptomatic persistent generalised lymphadenopaty, or AIDS related complex (ARC) patients was evaluated. Twenty patients were randomly assigned to receive only ZDV (1st group) or ZDV together with HIV-1-specific TF (2nd group). HIV-1-specific TF was administered orally at 2 × 107 cell equivalent daily for 15 days, and thereafter once a week for up to 6 months. There were no significant differences between the two groups in clinical evolution, red blood cells, haemoglobin, lymphocytes, CD20 subset, transaminases,β-2-microglobulin, p24 antigen. White blood cells, CD8 lymphocytes as well as IL-2 levels increased in the second group, while the CD4 subset increased in the first group. The combination treatment with ZDV and TF appeared to be safe and well tolerated. Furthermore, levels of serum cytokines were investigated in 10 patients (8 asymptomatic and 2 ARC) treated with ZDV, and compared with 5 patients of the 2nd group (3 asymptomatic and 2 ARC) treated with ZDV plus HIV-1-specific TF. Peripheral lymphocytes, CD4, CD8 subsets, IL-2, TNFα, IL-6, p24 antigen, IL-2 soluble lymphocyte receptors (sR), CD4sR, CD8sR and ß-2-microglobulin were evaluated at the baseline and at the 3rd month. The CD4 subset was not significantly different in the two groups, whilst IL-2 increased in the 2nd group receiving ZDV plus TF, suggesting an activation of the Th1 secretion pattern.

Collaboration


Dive into the Giancarlo Pizza's collaboration.

Top Co-Authors

Avatar

Dimitri Viza

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul H. Levine

George Washington University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

H. Hugh Fudenberg

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dharam V. Ablashi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Bruno Nardo

Sapienza University of Rome

View shared research outputs
Researchain Logo
Decentralizing Knowledge